Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 1, 2009, Pages 61-67

  Herrmann, Edwin ^a   Gerss, Joachim ^a   Bierer, Stefan ^a   Köpke, Thomas ^a   Bolenz, Christian ^b   Hertle, Lothar ^a   Wülfing, Christian ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Kidney cancer; Quality of life; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; INSOMNIA; KIDNEY CANCER; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HEALTH SURVEYS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDINES; PYRROLES; QUALITY OF LIFE; QUESTIONNAIRES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56649114461     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0438-7     Document Type: Article

References (19)

1. NK Aaronson S Ahmedza B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376
2. J Atzpodien T Kuchler T Wandert M Reitz 2003 Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome Br J Cancer 89 50 54
3. R Bukowski D Cella K Gondek B Escudier 2007 Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer Am J Clin Oncol 30 220 227
4. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Michaelson MD, Motzer RJ (2007) Quality of life (QoL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-alpha). Proc Asscoc J Clin Oncol 25:345s (Abstract 6594)
5. TK Choueiri A Plantade P Elson S Negrier A Ravaud S Oudard M Zhou BI Rini RM Bukowski B Escudier 2008 Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 127 131
6. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134
7. RC Flanigan SE Salmon BA Blumenstein SI Bearman V Roy PC McGrath JR Caton N Munshi ED Crawford 2001 Nephrectomy followed by interferonalfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655 1659
8. A Guzelant T Goksel S Ozkok S Tasbakan T Aysan A Bottomley 2004 The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30 Eur J Cancer Care 13 135 144
9. H Heinzer TS Mir E Huland H Huland 1999 Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy J Clin Oncol 17 3612 3620
10. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66
11. B Ljungberg DC Hanbury MA Kuczyk AS Merseburger PF Mulders JJ Patard IC Sinescu 2007 Renal cell carcinoma guideline Eur J Urol 51 1502 1510
12. GH Mickisch A Garin H van Poppel L de Prijck R Sylvester 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966 970
13. RJ Motzer J Bacik T Mariani P Russo M Mazumdar V Reuter 2002 Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology J Clin Oncol 20 2376 2381
14. RJ Motzer J Bacik LH Schwartz V Reuter P Russo S Marion M Mazumdar 2004 Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 454 463
15. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin MS Ginsberg ST Kim CM Baum SE DePrimo JZ Li CL Bello CP Theuer DJ George BI Rini 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24
16. RJ Motzer BI Rini RM Bukowski BD Curti DJ George GR Hudes BG Redman KA Margolin JR Merchan G Wilding MS Ginsberg J Bacik ST Kim CM Baum MD Michaelson 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524
17. K Mystakidou E Tsilika E Parpa O Kalaidopoulou V Symrniotis L Vlahos 2001 The EORTC core quality of life questionnaire QLQ-C30: validity and reliability when analysed with patients treated with palliative radiotherapy Int J Cancer 94 135 139
18. D Osoba G Rodrigues J Myles B Zee J Pater 1998 Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 139 144
19. A Trotti AD Colevas A Setser V Rusch D Jaques V Budach C Langer B Murphy R Cumberlin CN Coleman P Rubin 2003 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176 181